Enhancing CAR T‐cell therapy manufacturing efficiency through semi‐automated bioprocessing
Abstract Objectives Chimeric antigen receptor (CAR) T‐cell therapies have revolutionised the treatment of blood‐based malignancies. The use of manual CAR T‐cell manufacturing methods is one of the challenges that contributes to these delays. As CAR T therapy emerges as a potential first‐ or second‐l...
Saved in:
Main Authors: | Jason Isaacson, Prajakta Bhanap, Nicholas Putnam, Jasmine Padilla, Nujhat Fatima, Max Dotson, Danny Hayoun, Moloud Ahmadi, Gertrude Nonterah, Yongchang Ji |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Clinical & Translational Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1002/cti2.70025 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
CAR Beyond αβ T Cells: Unleashing NK Cells, Macrophages, and γδ T Lymphocytes Against Solid Tumors
by: Yunjia Xian, et al.
Published: (2025-06-01) -
Tracing the development of CAR-T cell design: from concept to next-generation platforms
by: Ahdab A. Alsaieedi, et al.
Published: (2025-07-01) -
Case report of non-gene editing CD7 CAR T cell therapy in CD7+ Sézary syndrome: preclinical validation and first-in-human use
by: Haichan Xu, et al.
Published: (2025-08-01) -
Bio-functional hydrogel coated membranes to decrease T-cell exhaustion in manufacturing of CAR T-cells
by: Aida López Ruiz, et al.
Published: (2025-06-01) -
Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion
by: Dennis Christoph Harrer, et al.
Published: (2025-06-01)